Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
NephroGenex
company
About
NephroGenex is a drug-development company focusing on kidney disease and progression of diabetic kidney disease.
- 11 - 50
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $3.30M
- Industries
- Biotechnology,Diabetes,Health Care
- Founded date
- Jan 1, 2004
- Number Of Employee
- 11 - 50
- Operating Status
- Active
NephroGenex is a drug-development company focusing on kidney disease. The Company is developing Pyridorinâ„¢ (pyridoxamine dihydrochloride) as a treatment to slow the progression of diabetic kidney disease.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$3.30M
NephroGenex has raised a total of
$3.30M
in funding over 2 rounds. Their latest funding was raised on
Jul 6, 2007 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 6, 2007 | Series A | $3.30M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
NephroGenex is funded by 1 investors.
Vanderbilt University Office of Investments
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Vanderbilt University Office of Investments
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
